ArticleTherapeutic advances in hematology2024

Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.

Justin Watts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.